310. Congenital anomalies syndrome Clinical trials / Disease details
Clinical trials : 10 / Drugs : 18 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01434745 (ClinicalTrials.gov) | September 2011 | 7/9/2011 | SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation | Smith-Lemli Opitz Syndrome: A Clinical Investigation of the Effect of Simvastatin in Patients Receiving Cholesterol Supplementation | Smith-Lemli-Opitz Syndrome | Drug: Simvastatin;Dietary Supplement: Lactose | Oregon Health and Science University | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | 1 Year | 89 Years | All | 1 | N/A | United States |
| 2 | NCT01356420 (ClinicalTrials.gov) | January 2011 | 11/5/2011 | Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz Syndrome | Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving Cholesterol Supplementation | Smith-Lemli-Opitz Syndrome | Dietary Supplement: Cholesterol supplementation | Oregon Health and Science University | NULL | Terminated | N/A | 85 Years | All | 21 | N/A | United States |